A recent scientific review suggests emerging treatments may offer hope against drug-resistant bacteria, particularly C. auris, which is spreading swiftly in U.S. hospitals and poses a significant global health risk.
Researchers from the Hackensack Meridian Center for Discovery and Innovation published their findings in early December, highlighting C. auris—commonly known as “superbug fungus”—as increasingly resistant to the human immune system.
This reinforces previous warnings from the CDC, which has labeled C. auris an “emergency antimicrobial threat,” marking it as the first fungal pathogen to receive such a designation. Infections are particularly rising in U.S. hospitals and long-term care facilities.
In 2025, nearly 7,000 confirmed cases were documented across multiple states, and it has been identified in at least 60 countries.
The review, featured in Microbiology and Molecular Biology Reviews, explains challenges in controlling such pathogens, pointing out outdated diagnostics and limited treatment options. Conducted by Dr. Neeraj Chauhan of Hackensack Meridian CDI, Dr. Anuradha Chaudhary from the University of Delhi, and Dr. Michael Lionakis from the National Institutes of Health, the study emphasizes the urgent need for novel antifungal medications and improved diagnostic methods.
Researchers advocate for better awareness and surveillance of fungal diseases, especially in areas with fewer resources, asserting that these advances could enhance patient outcomes for those afflicted with opportunistic fungal infections.
C. auris first emerged in Japan in 2009 and has since spread to numerous countries, leading to some hospital intensive care units being shut down due to outbreaks. The fungus primarily threatens individuals who are already critically ill, particularly those on ventilators or with compromised immune systems, with estimates suggesting it could be fatal for around half of infected patients.
Unlike many other fungi, C. auris can persist on human skin and adhere to hospital environments, facilitating its spread in healthcare settings. It’s particularly challenging due to its resistance to various antifungal treatments and has already shown resilience to many available drugs.
However, there’s cautious optimism as some ongoing research studies aim to identify weaknesses in C. auris. One study from the University of Exeter discovered that the fungus activates certain genes to extract iron during infections. Researchers believe that targeting this process could be a potential method to combat C. auris effectively.
Experts recommend strict infection control measures, prompt detection, and continuous investment in new treatments as critical components in managing C. auris. Fortunately, health authorities stress that it does not pose risks to healthy individuals. Further insights and comments from CDI researchers and other experts are still being sought.
